Section 162: Advanced Antioxidant and Redox Therapy in CBS/PSP

Migration, Crosslink

📖

Section 162: Advanced Antioxidant and Redox Therapy in CBS/PSP

active

wiki page Created: 2026-04-02T07:18:58 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-section-162-advanced-a

📖 Wiki Page

therapeutic5600 wordssynced 2026-04-02

Section 162: Advanced Antioxidant and Redox Therapy in CBS/PSP

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Section 162: Advanced Antioxidant and Redox Therapy in CBS/PSP</th>
</tr>
<tr>
<td class="label">Marker</td>
<td>Finding in CBS/PSP</td>
</tr>
<tr>
<td class="label">8-OHdG (DNA oxidation)</td>
<td>Elevated in substantia nigra</td>
</tr>
<tr>
<td class="label">4-HNE (lipid peroxidation)</td>
<td>Increased in basal ganglia</td>
</tr>
<tr>
<td class="label">Protein carbonyls</td>
<td>Elevated in affected regions</td>
</tr>
<tr>
<td class="label">3-nitrotyrosine</td>
<td>Prominent in neurons</td>
</tr>
<tr>
<td class="label">GSH/GSSG ratio</td>
<td>Decreased</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Recommendation</td>
</tr>
<tr>
<td class="label">Dose</td>
<td>100-200 mg daily (broccoli seed extract) or 600-1200 mg/day cruciferous vegetables equivalent</td>
</tr>
<tr>
<td class="label">Timing</td>
<td>With meals; divided doses (split BID for sustained NRF2 activation)</td>
</tr>
<tr>
<td class="label">Duration</td>
<td>Minimum 8 weeks for effect; 12-24 weeks for full benefit</td>
</tr>
<tr>
<td class="label">Monitoring</td>
<td>NfL at baseline and 12 weeks; GCLM expression in PBMCs</td>
</tr>
<tr>
<td class="label">Interactions</td>
<td>May affect CYP2C9 substrates; enhances levodopa effect</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Recommendatio

...

Section 162: Advanced Antioxidant and Redox Therapy in CBS/PSP

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Section 162: Advanced Antioxidant and Redox Therapy in CBS/PSP</th>
</tr>
<tr>
<td class="label">Marker</td>
<td>Finding in CBS/PSP</td>
</tr>
<tr>
<td class="label">8-OHdG (DNA oxidation)</td>
<td>Elevated in substantia nigra</td>
</tr>
<tr>
<td class="label">4-HNE (lipid peroxidation)</td>
<td>Increased in basal ganglia</td>
</tr>
<tr>
<td class="label">Protein carbonyls</td>
<td>Elevated in affected regions</td>
</tr>
<tr>
<td class="label">3-nitrotyrosine</td>
<td>Prominent in neurons</td>
</tr>
<tr>
<td class="label">GSH/GSSG ratio</td>
<td>Decreased</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Recommendation</td>
</tr>
<tr>
<td class="label">Dose</td>
<td>100-200 mg daily (broccoli seed extract) or 600-1200 mg/day cruciferous vegetables equivalent</td>
</tr>
<tr>
<td class="label">Timing</td>
<td>With meals; divided doses (split BID for sustained NRF2 activation)</td>
</tr>
<tr>
<td class="label">Duration</td>
<td>Minimum 8 weeks for effect; 12-24 weeks for full benefit</td>
</tr>
<tr>
<td class="label">Monitoring</td>
<td>NfL at baseline and 12 weeks; GCLM expression in PBMCs</td>
</tr>
<tr>
<td class="label">Interactions</td>
<td>May affect CYP2C9 substrates; enhances levodopa effect</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Recommendation</td>
</tr>
<tr>
<td class="label">Dose</td>
<td>250-500 mg daily (trans-resveratrol)</td>
</tr>
<tr>
<td class="label">Bioavailability</td>
<td>Low; use nanoparticle orpiperine formulations</td>
</tr>
<tr>
<td class="label">Timing</td>
<td>With fatty meals</td>
</tr>
<tr>
<td class="label">Duration</td>
<td>12+ weeks for cognitive effects</td>
</tr>
<tr>
<td class="label">Interactions</td>
<td>Significant with CYP3A4 substrates</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Recommendation</td>
</tr>
<tr>
<td class="label">Dose</td>
<td>300-500 mg daily (standardized extract)</td>
</tr>
<tr>
<td class="label">Timing</td>
<td>Between meals (empty stomach)</td>
</tr>
<tr>
<td class="label">Duration</td>
<td>Long-term use acceptable</td>
</tr>
<tr>
<td class="label">Interactions</td>
<td>Moderate with CYP3A4, CYP2C9</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>NRF2 Potency</td>
</tr>
<tr>
<td class="label">Sulforaphane</td>
<td>+++</td>
</tr>
<tr>
<td class="label">Bardoxolone methyl</td>
<td>++++</td>
</tr>
<tr>
<td class="label">Dimethyl fumarate</td>
<td>+++</td>
</tr>
<tr>
<td class="label">Resveratrol</td>
<td>++</td>
</tr>
<tr>
<td class="label">EGCG</td>
<td>++</td>
</tr>
<tr>
<td class="label">Trial ID</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">NCT03477136</td>
<td>II</td>
</tr>
<tr>
<td class="label">NCT02255137</td>
<td>II</td>
</tr>
<tr>
<td class="label">NCT02036970</td>
<td>I</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Recommendation</td>
</tr>
<tr>
<td class="label">Dose</td>
<td>10-150 mg daily (dose-escalation design)</td>
</tr>
<tr>
<td class="label">Timing</td>
<td>Morning with food</td>
</tr>
<tr>
<td class="label">Duration</td>
<td>12-48 weeks typical</td>
</tr>
<tr>
<td class="label">Monitoring</td>
<td>NfL at baseline, 12 weeks; liver and renal function</td>
</tr>
<tr>
<td class="label">Interactions</td>
<td>Avoid with strong CYP3A4 inducers; potential interaction with levodopa</td>
</tr>
<tr>
<td class="label">Trial ID</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">NCT02960727</td>
<td>II</td>
</tr>
<tr>
<td class="label">NCT03425656</td>
<td>II</td>
</tr>
<tr>
<td class="label">NCT05182658</td>
<td>II</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Recommendation</td>
</tr>
<tr>
<td class="label">Dose</td>
<td>120-240 mg twice daily (titrate from 120 mg)</td>
</tr>
<tr>
<td class="label">Timing</td>
<td>With food; avoid fasting</td>
</tr>
<tr>
<td class="label">Duration</td>
<td>Long-term (MS indication established safety)</td>
</tr>
<tr>
<td class="label">Monitoring</td>
<td>NfL at baseline and 12 weeks; CBC for lymphopenia</td>
</tr>
<tr>
<td class="label">Interactions</td>
<td>Generally favorable; minimal CYP interactions</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">MnTBAP</td>
<td>SOD mimetic, peroxynitrite scavenger</td>
</tr>
<tr>
<td class="label">EUK-134</td>
<td>SOD + catalase mimetic (salen-manganese)</td>
</tr>
<tr>
<td class="label">EUK-8</td>
<td>SOD + catalase mimetic</td>
</tr>
<tr>
<td class="label">MitoQ</td>
<td>Mitochondria-targeted ubiquinone</td>
</tr>
<tr>
<td class="label">MitoTEMPO</td>
<td>Mitochondria-targeted SOD mimetic</td>
</tr>
<tr>
<td class="label">SkQ1 (Plastoquinone)</td>
<td>Mitochondria-targeted plastoquinone</td>
</tr>
<tr>
<td class="label">Trial ID</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">Not registered</td>
<td>II</td>
</tr>
<tr>
<td class="label">Not registered</td>
<td>II</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Recommendation</td>
</tr>
<tr>
<td class="label">Dose</td>
<td>10-40 mg daily (mitoquinone mesylate)</td>
</tr>
<tr>
<td class="label">Form</td>
<td>MitoQ (not regular CoQ10) — targeted delivery</td>
</tr>
<tr>
<td class="label">Timing</td>
<td>Empty stomach or with small meal</td>
</tr>
<tr>
<td class="label">Duration</td>
<td>6-12 months minimum</td>
</tr>
<tr>
<td class="label">Monitoring</td>
<td>NfL at baseline, 12 weeks; motor assessments</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Recommendation</td>
</tr>
<tr>
<td class="label">Dose</td>
<td>600-1200 mg daily (oral); 600-1800 mg for high oxidative stress</td>
</tr>
<tr>
<td class="label">Forms</td>
<td>capsules, tablets, effervescent</td>
</tr>
<tr>
<td class="label">Timing</td>
<td>Empty stomach, 30 min before meals</td>
</tr>
<tr>
<td class="label">Duration</td>
<td>Long-term; 6+ months for full effect</td>
</tr>
<tr>
<td class="label">Evidence</td>
<td>Strong for Parkinson's disease; emerging for CBS/PSP</td>
</tr>
<tr>
<td class="label">Split dosing</td>
<td>600 mg BID preferred over 1200 mg once daily</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">NAC</td>
<td>600-1200 mg/day</td>
</tr>
<tr>
<td class="label">NAC + glycine</td>
<td>600 mg + 600 mg</td>
</tr>
<tr>
<td class="label">NAC + glutamine</td>
<td>600 mg + 500-1000 mg</td>
</tr>
<tr>
<td class="label">Full trio (NAC + glycine + glutamine)</td>
<td>600+600+600 mg</td>
</tr>
<tr>
<td class="label">S-adenosyl-L-methionine (SAMe)</td>
<td>400-800 mg</td>
</tr>
<tr>
<td class="label">Alpha-lipoic acid</td>
<td>300-600 mg</td>
</tr>
<tr>
<td class="label">N-acetyl-cysteine ethyl ester (NACET)</td>
<td>300-600 mg</td>
</tr>
<tr>
<td class="label">Setria glutathione</td>
<td>250-500 mg</td>
</tr>
<tr>
<td class="label">Whey protein (cysteine-rich)</td>
<td>20-30 g/day</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Target</td>
</tr>
<tr>
<td class="label">GSH/GSSG ratio</td>
<td>Increase</td>
</tr>
<tr>
<td class="label">8-OHdG</td>
<td>Decrease</td>
</tr>
<tr>
<td class="label">NfL</td>
<td>Stabilize</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">FeTPPS</td>
<td>Peroxynitrite decomposition catalyst</td>
</tr>
<tr>
<td class="label">UA</td>
<td>Uric acid (endogenous scavenger)</td>
</tr>
<tr>
<td class="label">EGCG</td>
<td>Direct and indirect scavenging</td>
</tr>
<tr>
<td class="label">MnTBAP</td>
<td>SOD mimetic + peroxynitrite scavenger</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Target</td>
</tr>
<tr>
<td class="label">MitoQ (mitoquinone)</td>
<td>Inner mitochondrial membrane</td>
</tr>
<tr>
<td class="label">MitoTEMPO</td>
<td>Matrix and membranes</td>
</tr>
<tr>
<td class="label">idebenone</td>
<td>Complex I + free radical</td>
</tr>
<tr>
<td class="label">CoQ10</td>
<td>Electron transport chain</td>
</tr>
<tr>
<td class="label">Redox state</td>
<td>Reduced (active)</td>
</tr>
<tr>
<td class="label">Bioavailability</td>
<td>High (3-5x better absorption)</td>
</tr>
<tr>
<td class="label">Conversion required</td>
<td>None</td>
</tr>
<tr>
<td class="label">Stability</td>
<td>Oxidizes rapidly in air</td>
</tr>
<tr>
<td class="label">Recommended form</td>
<td>Yes — for supplements</td>
</tr>
<tr>
<td class="label">Age factor</td>
<td>Absorption declines with age; ubiquinol better</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Recommendation</td>
</tr>
<tr>
<td class="label">Form</td>
<td>Ubiquinol (reduced) — preferred</td>
</tr>
<tr>
<td class="label">Dose</td>
<td>100-300 mg/day (ubiquinol) or 300-900 mg/day (ubiquinone)</td>
</tr>
<tr>
<td class="label">Timing</td>
<td>With fatty meals; split doses for >200 mg</td>
</tr>
<tr>
<td class="label">Duration</td>
<td>6+ months minimum</td>
</tr>
<tr>
<td class="label">Monitoring</td>
<td>NfL at baseline, 12 weeks; motor assessments</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Recommendation</td>
</tr>
<tr>
<td class="label">Dose</td>
<td>300-600 mg/day</td>
</tr>
<tr>
<td class="label">Timing</td>
<td>Empty stomach for absorption</td>
</tr>
<tr>
<td class="label">Form</td>
<td>R-lipoic acid</td>
</tr>
<tr>
<td class="label">Interactions</td>
<td>Thyroid medication, chemotherapy</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Utility in CBS/PSP</td>
</tr>
<tr>
<td class="label">NfL</td>
<td>Primary progression marker</td>
</tr>
<tr>
<td class="label">NfH</td>
<td>Complementary marker</td>
</tr>
<tr>
<td class="label">pNfH</td>
<td>Progression marker</td>
</tr>
<tr>
<td class="label">Complement</td>
<td>Emerging</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Source</td>
</tr>
<tr>
<td class="label">8-OHdG</td>
<td>Urine, CSF, serum</td>
</tr>
<tr>
<td class="label">4-HNE</td>
<td>Blood, CSF</td>
</tr>
<tr>
<td class="label">GSH/GSSG ratio</td>
<td>Blood</td>
</tr>
<tr>
<td class="label">Protein carbonyls</td>
<td>Blood</td>
</tr>
<tr>
<td class="label">3-nitrotyrosine</td>
<td>CSF, blood</td>
</tr>
<tr>
<td class="label">Test</td>
<td>Baseline</td>
</tr>
<tr>
<td class="label">Serum NfL</td>
<td>Yes</td>
</tr>
<tr>
<td class="label">8-OHdG (urine)</td>
<td>Yes</td>
</tr>
<tr>
<td class="label">GSH/GSSG ratio</td>
<td>Yes</td>
</tr>
<tr>
<td class="label">Liver/renal function</td>
<td>Yes</td>
</tr>
<tr>
<td class="label">CBC (if on DMF)</td>
<td>Yes</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Tissue</td>
</tr>
<tr>
<td class="label">GCLM expression</td>
<td>PBMCs</td>
</tr>
<tr>
<td class="label">NQO1 expression</td>
<td>PBMCs</td>
</tr>
<tr>
<td class="label">HO-1 expression</td>
<td>PBMCs</td>
</tr>
<tr>
<td class="label">GCLC expression</td>
<td>PBMCs</td>
</tr>
<tr>
<td class="label">NRF2 nuclear translocation</td>
<td>PBMCs (WB)</td>
</tr>
<tr>
<td class="label">Timepoint</td>
<td>Assessment</td>
</tr>
<tr>
<td class="label">Baseline</td>
<td>NfL, oxidative markers</td>
</tr>
<tr>
<td class="label">8-12 weeks</td>
<td>NfL (primary)</td>
</tr>
<tr>
<td class="label">24 weeks</td>
<td>Full oxidative panel</td>
</tr>
<tr>
<td class="label">Antioxidant</td>
<td>Interaction</td>
</tr>
<tr>
<td class="label">Sulforaphane</td>
<td>May enhance dopaminergic activity</td>
</tr>
<tr>
<td class="label">Bardoxolone methyl</td>
<td>Potential additive dopaminergic effect</td>
</tr>
<tr>
<td class="label">Dimethyl fumarate</td>
<td>Generally safe</td>
</tr>
<tr>
<td class="label">Resveratrol</td>
<td>May enhance effect</td>
</tr>
<tr>
<td class="label">EGCG</td>
<td>May reduce absorption</td>
</tr>
<tr>
<td class="label">NAC</td>
<td>May enhance effect</td>
</tr>
<tr>
<td class="label">CoQ10 (ubiquinol)</td>
<td>May enhance effect</td>
</tr>
<tr>
<td class="label">Alpha-lipoic acid</td>
<td>Generally safe</td>
</tr>
<tr>
<td class="label">MitoQ</td>
<td>Generally safe</td>
</tr>
<tr>
<td class="label">Antioxidant</td>
<td>Interaction</td>
</tr>
<tr>
<td class="label">Bardoxolone methyl</td>
<td>Theoretical combined effect</td>
</tr>
<tr>
<td class="label">Dimethyl fumarate</td>
<td>Generally safe</td>
</tr>
<tr>
<td class="label">Resveratrol</td>
<td>Theoretical additive MAO inhibition</td>
</tr>
<tr>
<td class="label">EGCG</td>
<td>Possible mild interaction</td>
</tr>
<tr>
<td class="label">Sulforaphane</td>
<td>Generally safe</td>
</tr>
<tr>
<td class="label">NAC</td>
<td>Generally safe</td>
</tr>
<tr>
<td class="label">MitoQ</td>
<td>Generally safe</td>
</tr>
<tr>
<td class="label">Medication Class</td>
<td>Antioxidant Concern</td>
</tr>
<tr>
<td class="label">Warfarin</td>
<td>Resveratrol, high-dose EGCG, bardoxolone methyl</td>
</tr>
<tr>
<td class="label">DOACs</td>
<td>Resveratrol, bardoxolone methyl</td>
</tr>
<tr>
<td class="label">Statins</td>
<td>Resveratrol (CYP3A4), bardoxolone methyl</td>
</tr>
<tr>
<td class="label">SSRIs</td>
<td>Multiple (serotonin syndrome rare)</td>
</tr>
<tr>
<td class="label">Beta-blockers</td>
<td>EGCG</td>
</tr>
<tr>
<td class="label">CYP3A4 inducers</td>
<td>Bardoxolone methyl (rifampin reduces by 70%)</td>
</tr>
<tr>
<td class="label">Immunosuppressants</td>
<td>Dimethyl fumarate</td>
</tr>
<tr>
<td class="label">Live vaccines</td>
<td>Dimethyl fumarate</td>
</tr>
<tr>
<td class="label">Priority</td>
<td>Agent</td>
</tr>
<tr>
<td class="label">1</td>
<td>Sulforaphane</td>
</tr>
<tr>
<td class="label">2</td>
<td>NAC</td>
</tr>
<tr>
<td class="label">3</td>
<td>CoQ10</td>
</tr>
<tr>
<td class="label">Addition</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">Resveratrol</td>
<td>250 mg</td>
</tr>
<tr>
<td class="label">EGCG</td>
<td>300 mg</td>
</tr>
<tr>
<td class="label">ALA</td>
<td>300 mg</td>
</tr>
<tr>
<td class="label">Week</td>
<td>Assessment</td>
</tr>
<tr>
<td class="label">0</td>
<td>Baseline NfL</td>
</tr>
<tr>
<td class="label">4</td>
<td>Symptom review</td>
</tr>
<tr>
<td class="label">8</td>
<td>NfL</td>
</tr>
<tr>
<td class="label">12</td>
<td>Full panel</td>
</tr>
<tr>
<td class="label">24</td>
<td>Comprehensive</td>
</tr>
<tr>
<td class="label">Component</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">Sulforaphane</td>
<td>100-150 mg</td>
</tr>
<tr>
<td class="label">NAC</td>
<td>600 mg</td>
</tr>
<tr>
<td class="label">Ubiquinol (CoQ10)</td>
<td>100-200 mg</td>
</tr>
<tr>
<td class="label">Alpha-lipoic acid</td>
<td>300 mg</td>
</tr>
<tr>
<td class="label">Component</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">Bardoxolone methyl</td>
<td>10-50 mg</td>
</tr>
<tr>
<td class="label">Sulforaphane</td>
<td>100 mg</td>
</tr>
<tr>
<td class="label">NAC</td>
<td>600 mg</td>
</tr>
<tr>
<td class="label">Ubiquinol</td>
<td>100 mg</td>
</tr>
<tr>
<td class="label">Component</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">MitoQ</td>
<td>20 mg</td>
</tr>
<tr>
<td class="label">Ubiquinol</td>
<td>200 mg</td>
</tr>
<tr>
<td class="label">Alpha-lipoic acid</td>
<td>600 mg</td>
</tr>
<tr>
<td class="label">NAC</td>
<td>900 mg</td>
</tr>
<tr>
<td class="label">Sulforaphane</td>
<td>100 mg</td>
</tr>
<tr>
<td class="label">Component</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">Dimethyl fumarate</td>
<td>120-240 mg BID</td>
</tr>
<tr>
<td class="label">NAC</td>
<td>600 mg</td>
</tr>
<tr>
<td class="label">Ubiquinol</td>
<td>100 mg</td>
</tr>
<tr>
<td class="label">Quercetin</td>
<td>500 mg</td>
</tr>
<tr>
<td class="label">Component</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">Sulforaphane</td>
<td>100 mg BID</td>
</tr>
<tr>
<td class="label">EGCG</td>
<td>300 mg</td>
</tr>
<tr>
<td class="label">NAC</td>
<td>600 mg</td>
</tr>
<tr>
<td class="label">Resveratrol</td>
<td>250 mg</td>
</tr>
</table>

Overview

Oxidative stress and redox imbalance play critical roles in the pathogenesis of corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP). These 4R-tauopathies demonstrate prominent mitochondrial dysfunction, impaired antioxidant defenses, and elevated reactive oxygen species (ROS) that contribute to neuronal death[@chen2024mito]. While basic antioxidant approaches have been explored, this section focuses on advanced redox therapeutic strategies targeting specific molecular pathways: NRF2 activation, endogenous antioxidant enzyme enhancement, glutathione optimization, peroxynitrite scavenging, and mitochondrial-targeted antioxidants.

The therapeutic window in CBS/PSP requires careful attention to oxidative stress biomarkers, particularly neurofilament light chain (NfL), to monitor treatment response and disease progression[@blach2024nfl]. Additionally, drug interactions between antioxidants and standard movement disorder medications—including levodopa and MAO-B inhibitors like rasagiline—must be carefully managed to optimize outcomes[@johnson2024interactions].

1. The Redox Imbalance in CBS/PSP

1.1 Oxidative Stress Markers

CBS and PSP brains demonstrate multiple hallmarks of redox imbalance:

1.2 Mitochondrial Dysfunction

Mitochondrial deficits in CBS/PSP include:

Complex I inhibition leading to reduced ATP production
Impaired calcium buffering capacity
Increased susceptibility to excitotoxicity
Altered mitochondrial dynamics (fission/fusion)
Reduced mitophagy efficiency

1.3 Therapeutic Implications

The interconnected nature of redox dysfunction suggests that multi-target approaches may be more effective than single-antioxidant strategies. Key pathways to target include:

NRF2-ARE pathway: Master regulator of antioxidant response

Endogenous antioxidant enzymes: SOD, catalase, glutathione peroxidase

Glutathione system: Primary cellular redox buffer

Peroxynitrite detoxification: Preventing nitrosative damage

Mitochondrial antioxidants: Targeted ROS scavenging

2. NRF2 Activators: The Master Antioxidant Switch

2.1 Biology of NRF2 Activation

Nuclear factor erythroid 2–related factor 2 (NRF2) is a transcription factor that regulates expression of over 200 antioxidant and cytoprotective genes through the antioxidant response element (ARE)[@cuendet2024nrf2]. In CBS/PSP, NRF2 signaling is frequently impaired due to:

KEAP1-mediated sequestration
Reduced nuclear translocation
Epigenetic silencing of target genes

Pharmacologic NRF2 activation can restore expression of:

Glutathione synthesis enzymes (GCLM, GCLC)
Heme oxygenase-1 (HO-1)
NAD(P)H quinone dehydrogenase 1 (NQO1)
Superoxide dismutase (SOD) isoforms
Thioredoxin and peroxiredoxins

2.2 Sulforaphane

Sulforaphane (SFN), an isothiocyanate derived from cruciferous vegetables, is one of the most potent naturally occurring NRF2 activators[@liu2024sulforaphane].

Mechanisms of Action

Covalent modification of KEAP1 cysteine residues
Rapid NRF2 nuclear translocation
Sustained ARE gene expression
Additional anti-inflammatory effects via NF-κB inhibition

Clinical Considerations for CBS/PSP

Dosing Optimization:

Broccoli seed extract: Standardized to 10-15% glucoraphanin content; 100 mg provides ~15 mg sulforaphane
Cruciferous vegetable equivalent: 600-1200 mg/day sulforaphane corresponds to roughly 300-600 g of fresh broccoli (approximately 2-3 cups of steamed broccoli daily)
Bioavailability: Divided dosing (BID) maintains more stable NRF2 activation than single daily dose; sulforaphane has a half-life of approximately 2-3 hours
Cycle off: Consider 1-2 week washout every 3 months to prevent NRF2 pathway desensitization

Important Drug Interactions:

Levodopa: Sulforaphane may enhance dopaminergic activity; monitor for increased "on" time or dyskinesias
Rasagiline: Theoretical interaction; use caution and monitor blood pressure
Anticoagulants: May potentiate warfarin effect; monitor INR closely

Efficacy Evidence

Preclinical models demonstrate:

Reduced tau phosphorylation in SFN-treated neurons
Decreased 4-HNE accumulation
Improved mitochondrial function
Enhanced autophagy flux

2.3 Resveratrol

Resveratrol (3,5,4'-trihydroxystilbene) activates NRF2 through multiple mechanisms and additionally stimulates SIRT1, providing synergistic neuroprotective effects[@park2024resveratrol].

Mechanisms Beyond NRF2

SIRT1 activation (deacetylates NRF2, PGC-1α)
Mitochondrial biogenesis promotion
Amyloid-beta and tau aggregation inhibition
Anti-inflammatory effects

Clinical Considerations

Important Drug Interactions:

Levodopa: May enhance effect; dose reduction may be needed
Rasagiline: Potential additive MAO inhibition; avoid combination or monitor closely
Anticoagulants: Strong interaction; avoid with warfarin, direct oral anticoagulants
Statins: May increase statin levels (CYP3A4)

2.4 Epigallocatechin-3-Gallate (EGCG)

EGCG, the most abundant catechin in green tea, provides NRF2 activation plus direct tau aggregation inhibition[@tanaka2024egcg].

Dual Mechanisms

NRF2 activation via KEAP1 modification
Direct tau oligomerization inhibition
Metal chelation (iron, copper)
Anti-apoptotic effects

Clinical Considerations

Important Drug Interactions:

Levodopa: May affect absorption; separate by 2 hours
Rasagiline: Additive effects theoretically possible; monitor
Beta-blockers: May increase propranolol levels
Iron supplements: Separate by 3-4 hours (chelation)

2.5 NRF2 Activator Comparison

2.6 Clinical Trials: Bardoxolone Methyl and Dimethyl Fumarate

Bardoxolone Methyl (CDDO-Me)

Bardoxolone methyl is a potent synthetic triterpenoid NRF2 activator with significantly higher potency than natural compounds[@cuendet2024nrf2]. It covalently modifies KEAP1 cysteine residues, leading to robust and sustained NRF2 activation.

Clinical Trial Evidence:

Clinical Considerations for CBS/PSP:

Important Drug Interactions:

Levodopa: Limited data but potential additive dopaminergic effects; monitor motor response
Rasagiline: Theoretical concern about combined MAO-B + NRF2 effects; use caution
Anticoagulants: May potentiate warfarin effect via CYP3A4; monitor INR
Rifampin: Strong CYP3A4 inducer; co-administration reduces bardoxolone exposure by ~70%

Efficacy in Tauopathies:
Preclinical models of 4R-tauopathies demonstrate that bardoxolone methyl reduces tau phosphorylation, suppresses microglial activation, and improves motor function. The potent anti-inflammatory properties (NRF2 + NF-κB dual inhibition) make it particularly attractive for CBS/PSP where both oxidative stress and neuroinflammation are prominent.

Dimethyl Fumarate (Tecfidera)

Dimethyl fumarate (DMF) is an FDA-approved treatment for multiple sclerosis that provides substantial human safety data supporting repurposing for CBS/PSP[@cuendet2024nrf2].

Mechanisms Beyond NRF2:

Immune modulation: Shifts toward anti-inflammatory (M2) microglial phenotype
Neuroprotection: Supports mitochondrial function and ATP production
Myelin preservation: Relevant for white matter involvement in CBS

Clinical Trial Evidence:

Clinical Considerations for CBS/PSP:

Important Drug Interactions:

Levodopa: Generally safe; no significant pharmacokinetic interaction
Rasagiline: Generally safe; no significant interaction
Immunosuppressants: Caution with other immunosuppressive agents
Live vaccines: May reduce vaccine efficacy

Special Consideration for CBS/PSP:
DMF's established safety profile and CNS penetration make it a practical choice. The immune-modulating effects may provide added benefit in CBS/PSP where both oxidative stress and neuroinflammation drive pathology. Gastrointestinal side effects (flushing, diarrhea) can be managed with aspirin pretreatment and dose titration.

3. Superoxide Dismutase and Catalase Enhancement

3.1 Endogenous Enzyme Biology

Superoxide dismutase (SOD) and catalase represent the primary enzymatic defense against ROS:

SOD: Converts superoxide (O₂⁻) to hydrogen peroxide (H₂O₂)
Catalase: Converts H₂O₂ to water and oxygen

In CBS/PSP, these enzymes show:

Reduced activity in affected brain regions
Post-translational modification (oxidation, nitration)
Genetic polymorphisms affecting expression

3.2 Pharmacologic Enhancement Strategies

Direct Enzyme Mimetics

Synthetic SOD/catalase mimetics offer advantages over native enzymes[@kim2024sod]:

Manganese porphyrins (MnPorphyrins)
Salen-manganese complexes (EUK-8, EUK-134)
Fullerenes

Promising Compounds

EUK-134: Dual SOD/Catalase Mimetic

EUK-134 is a salen-manganese complex that simultaneously mimics both superoxide dismutase and catalase activities, providing comprehensive ROS detoxification[@kim2024sod].

Mechanism:

Catalyzes conversion of superoxide to hydrogen peroxide (SOD activity)
Further converts hydrogen peroxide to water and oxygen (catalase activity)
Crosses blood-brain barrier in preclinical models
Does not undergo redox cycling (unlike some antioxidants)

Preclinical Evidence:

Neuroprotection in MPTP and 6-OHDA models of parkinsonism
Reduced lipid peroxidation and protein carbonyl formation
Improved mitochondrial function and survival in cultured neurons
Synergistic with NRF2 activators in dual-protection strategies

Clinical Considerations:

Currently in preclinical/early clinical development
Dose: Not established for human neurodegeneration; preclinical studies used 1-10 mg/kg
No current human data for CBS/PSP; participation in clinical trials recommended if available
Monitor for manganese-related effects (neurotoxicity at high doses) — theoretical concern with long-term use

MitoQ: Mitochondria-Targeted Ubiquinone

MitoQ consists of CoQ10 (ubiquinone) conjugated to a triphenylphosphonium cation that drives accumulation within mitochondria up to 10-fold[@chen2024mito].

Mechanism:

Targets to inner mitochondrial membrane via membrane potential
Protects Complex I from oxidation damage
Supports ATP production
Reduces apoptosis signaling

Clinical Evidence:

Clinical Considerations for CBS/PSP:

Important Drug Interactions:

Levodopa: Generally safe; some reports of enhanced effect
Rasagiline: Generally safe
Warfarin: May decrease INR; monitor

SkQ1: Plastoquinone Mitochondrial Antioxidant

SkQ1 (visomitin) is a mitochondria-targeted antioxidant consisting of plastoquinone linked to a SkQ (skyl)-type cation. It has been approved in Russia for ophthalmic conditions and is under investigation for neurodegeneration.

Mechanism:

Accumulates in mitochondria via phospholipid membrane potential
Scavenges superoxide at the site of generation
Prevents mitochondrial permeability transition
Reduces apoptosis

Evidence:

Approved in Russia (eye drops) for dry eye syndrome and glaucoma
Preclinical data in ALS and PD models
Ongoing investigation for CNS applications

Clinical Considerations:

Oral formulations under development for systemic use
Doses of 0.1-1 nmol/kg/day in preclinical studies
Not widely available outside Russia; clinical trial participation if available

Natural Enhancers

Quercetin: Upregulates SOD, catalase expression via NRF2; 500 mg daily
Curcumin: Enhances NRF2 and antioxidant enzymes; 500-1000 mg daily (bioavailable formulations)
Coffee extract: Chlorogenic acid effects; standard coffee consumption

3.3 Clinical Implementation

Recommended approach:

Baseline oxidative stress markers (NfL, 8-OHdG)

Start with natural enhancer (quercetin 500 mg daily) for 8 weeks

If progression continues, escalate to MitoQ 20 mg daily

Consider clinical trial for EUK-134 if available

Monitor NfL at 12-week intervals

4. Glutathione Optimization

4.1 Glutathione Biology in CBS/PSP

Glutathione (GSH), the most abundant cellular antioxidant, is critically depleted in CBS/PSP[@schmidt2024glutathione]:

GSH levels reduced 40-60% in substantia nigra
GCLM and GCLC expression downregulated
GSSG (oxidized form) accumulated
Relationship to disease severity established

The GSH Synthesis Pathway

Mermaid diagram (expand to render)

4.2 Glutathione Precursors

N-Acetylcysteine (NAC)

NAC remains the primary GSH precursor in clinical use[@agrawal2024nac]:

Mechanism:

Provides cysteine for GSH synthesis (rate-limiting precursor)
Directly scavenges ROS (nucleophilic properties)
Supports mucolytic effects; reduces mucus viscosity

Optimization:

Split dosing: 600 mg BID maintains more stable cysteine levels than single 1200 mg dose
With glycine and glutamine: Adding these amino acids provides additional substrates for GSH synthesis. Glycine is required at every step of GSH synthesis; glutamine supports glutamate production for GSH. Consider adding glycine 600-1200 mg and glutamine 500-1000 mg daily
Bioavailability: NAC has ~4-10% oral bioavailability due to first-pass metabolism; effervescent forms may improve absorption
With vitamin C: Vitamin C (500-1000 mg) helps maintain NAC in reduced form and provides additional antioxidant support

Drug Interactions:

Levodopa: May enhance effect; some patients report improved "on" time
Nitroglycerin: Potential additive hypotensive effect
Activated charcoal: Reduces NAC absorption; separate by 2 hours
Metformin: Theoretical concern about additive effects on GSH; monitor

Glutathione Precursors (Alternative)

Optimal Glutathione Optimization Strategy for CBS/PSP:

Start with NAC 600 mg BID as foundation

Add glycine 600 mg BID if GSH/GSSG ratio remains low

Consider adding alpha-lipoic acid 300 mg for recycling support

For severe depletion, add SAMe 400-600 mg in the morning

Monitor GSH/GSSG ratio at 8 weeks; target improvement of 20%+

4.3 Intravenous Glutathione

IV glutathione has been explored in movement disorders:

Dose: 600-2400 mg, 1-3 times weekly
Limited CNS penetration (debated)
May require blood-brain barrier permeation strategies

Caution: IV glutathione may cause:

Transient hypotension
Allergic reactions
Interaction with chemotherapy agents

4.4 Monitoring Glutathione Therapy

5. Peroxynitrite Scavenging

5.1 Peroxynitrite in CBS/PSP

Peroxynitrite (ONOO⁻), formed from superoxide and nitric oxide, is highly damaging:

Nitrates tyrosine residues (3-NT)
Inactivates mitochondrial enzymes
Triggers lipid peroxidation
Promotes tau nitration and aggregation

Evidence in CBS/PSP[@hernandez2024peroxynitrite]:

Elevated 3-nitrotyrosine in affected regions
Inducible nitric oxide synthase (iNOS) upregulation
Neuronal susceptibility to peroxynitrite toxicity

5.2 Scavenging Strategies

Pharmacologic Scavengers

Uric Acid Augmentation

Elevating uric acid (UA) provides neuroprotection:

Natural peroxynitrite scavenger
Associated with better outcomes in PD
Dietary strategies: purine-rich foods

Caution: UA elevation requires monitoring for:

Gout
Cardiovascular disease
Kidney stones

5.3 Clinical Recommendations

For peroxynitrite-targeted therapy:

Baseline assessment:

Serum uric acid
3-nitrotyrosine (research)
NfL

Therapeutic options:

Green tea EGCG: 300-500 mg/day
NAC: 600-1200 mg/day
Consider uric acid elevation if low

Monitoring:

Uric acid monthly during treatment
NfL at 12 weeks
Renal function

6. Mitochondrial Antioxidants

6.1 Mitochondria-Targeted Therapy

Mitochondria are both sources and targets of ROS in CBS/PSP[@chen2024mito]. Targeted antioxidants concentrate within mitochondria:

Key Compounds

6.2 Coenzyme Q10: Ubiquinol vs Ubiquinone

CoQ10 exists in two redox states: oxidized (ubiquinone) and reduced (ubiquinol). This distinction is critical for clinical efficacy[@chen2024mito].

Key Differences:

Clinical Evidence:

Ubiquinol demonstrated improved mitochondrial function in PD patients (10-100 mg range)[@chen2024mito]
Phase II trials used 300-1200 mg/day of ubiquinone; equivalent doses of ubiquinol would be 100-400 mg/day
PSP patients showed modest benefit in a 12-month trial at 600 mg/day (ubiquinone)

Clinical Considerations for CBS/PSP:

Special Considerations:

Patients over 60 benefit more from ubiquinol (reduced ability to convert ubiquinone)
Bioavailability varies widely between formulations; choose pharmaceutical-grade
Consider combining with alpha-lipoic acid for synergistic mitochondrial support
Drug interactions: May reduce warfarin INR; monitor coagulation

6.3 Alpha-Lipoic Acid

Alpha-lipoic acid (ALA) has unique properties:

Water and fat soluble
Regenerates other antioxidants (GSH, vitamins C/E)
Supports mitochondrial function

7. NET Biomarker Assessment

7.1 Neurofilament Light Chain (NfL)

NfL serves as a key biomarker for[@blach2024nfl]:

Disease progression in CBS/PSP
Treatment response to disease-modifying therapies
Axonal injury intensity

Interpretation in CBS/PSP:

Serum NfL is elevated in both CBS and PSP compared to healthy controls
CBS shows higher mean NfL than PSP, reflecting greater cortical involvement
NfL trajectory (slope over 6-12 months) correlates with clinical progression
NfL is the primary biomarker for monitoring antioxidant/redox therapy response

7.2 Neurofilament Heavy Chain (NfH) and Complement

7.3 Oxidative Stress Biomarkers (8-OHdG, 4-HNE, GSH/GSSG)

These serve as direct measures of redox status for antioxidant therapy monitoring:

Recommended Panel for Antioxidant Therapy Monitoring:

7.4 NRF2 Pathway Engagement Biomarkers

To assess whether NRF2-targeted therapy is actually engaging the pathway:

Clinical Utility:

GCLM and NQO1 expression in peripheral blood mononuclear cells (PBMCs) serve as surrogate markers of CNS NRF2 activation
These are used in clinical trials (NCT03477136, NCT02960727) to confirm target engagement
Can guide dose optimization — aim for 2-3 fold induction of target genes

7.5 Monitoring Recommendations

For patients on antioxidant/redox therapy:

Interpretation:

Stable/declining NfL: Continue current therapy
Rising NfL: Consider intensification or combination therapy

8. Drug Interactions with Standard CBS/PSP Medications

8.1 Levodopa Interactions

Multiple antioxidants affect levodopa pharmacokinetics and pharmacodynamics[@johnson2024interactions]:

8.2 Rasagiline Interactions

MAO-B inhibitor interactions:

Clinical Guidance:

Avoid high-dose resveratrol with rasagiline (MAO-B + potential serotonergic effects)
Monitor blood pressure with any NRF2 activator combination, especially with bardoxolone methyl
Report unusual sedation or serotonin-like symptoms
Combination of bardoxolone methyl + rasagiline requires careful monitoring due to overlapping pathways

8.3 Other Medication Interactions

8.4 Specific Drug-Drug Interaction Details

Bardoxolone methyl + Levodopa:
No formal drug-drug interaction study exists, but both agents affect dopaminergic pathways. Theoretical concern for enhanced dopamine effect leading to dyskinesias. If combining, start with reduced levodopa dose and titrate carefully.

Dimethyl fumarate + Immunosuppressants:
Dimethyl fumarate causes lymphopenia in some patients. Concurrent use with immunosuppressants may compound this effect. Monitor CBC regularly; discontinue if lymphocyte count falls below 500 cells/µL.

CoQ10 + Anticoagulants:
CoQ10 structurally resembles vitamin K2 and may reduce warfarin effectiveness. Separate from anticoagulant dosing by 12 hours. Monitor INR more frequently when starting or stopping CoQ10.

9. Integrated Treatment Protocol

9.1 Recommended Approach

Step 1: Baseline Assessment

Serum NfL
Oxidative stress markers (8-OHdG, 4-HNE)
Uric acid
Current medications review

Step 2: Initial Therapy

Step 3: Escalation (if needed)

9.2 Monitoring Schedule

9.3 Combination Antioxidant Protocols

Rationale: Combining antioxidants with complementary mechanisms may provide additive or synergistic neuroprotection in CBS/PSP. However, combination therapy requires careful attention to drug interactions, additive adverse effects, and cost.

Protocol A: Foundational Multi-Agent (Most Common)

Indications: Newly diagnosed CBS/PSP, patients naive to antioxidant therapy Duration: 6-12 months minimum; reassess at 12 weeks with NfL

Protocol B: NRF2-Focused (High NRF2 Pathway Engagement)

Indications: Moderate disease, inadequate response to Protocol A, confirmed NRF2 pathway dysfunction Duration: 3-6 months with intensive monitoring (NfL, liver/renal function, blood pressure) Caution: Requires movement disorder specialist oversight; avoid with rasagiline

Protocol C: Mitochondria-Focused (Prominent Energy Failure)

Indications: PSP phenotype (prominent postural instability, falls), elevated oxidative stress markers Duration: 3-6 months minimum

Protocol D: Dimethyl Fumarate-Based (Immune Modulation Focus)

Indications: CBS with prominent cortical involvement (asymmetric apraxia, alien limb), elevated NfL Duration: 6+ months; CBC monitoring required Caution: Monitor for lymphopenia; check CBC every 3 months

Protocol E: Synergistic NRF2 + Autophagy (Protein Clearance Focus)

Indications: CBS/PSP with prominent cortical dysfunction, high tau burden Duration: 3-6 months

Combining Protocols:

Start with Protocol A (foundational) for 8-12 weeks
If NfL is rising, escalate to Protocol B or C based on dominant pathology
Never combine Protocols B + D (overlapping mechanisms may increase adverse effects)
When combining, reduce doses by 20-30% and monitor closely

9.4 Special Populations

Elderly patients (>75):

Start with single agent
Lower doses initially
More frequent monitoring

Patients on multiple medications:

Review interactions before adding
Prefer agents with lower interaction risk (sulforaphane, NAC)
Coordinate with movement disorder specialist

10. Summary and Clinical Recommendations

Key Takeaways

NRF2 activators (sulforaphane, bardoxolone methyl, dimethyl fumarate, resveratrol, EGCG) represent the most comprehensive approach to redox therapy in CBS/PSP, with bardoxolone methyl being the most potent synthetic option and DMF offering the best-established safety profile

Glutathione optimization through NAC supplementation (with glycine, glutamine, and alpha-lipoic acid for recycling) provides foundational support for cellular antioxidant capacity

Mitochondrial antioxidants (MitoQ, SkQ1, ubiquinol CoQ10, alpha-lipoic acid) address the primary source of ROS in affected neurons with targeted delivery mechanisms

Synthetic SOD/catalase mimetics (EUK-134, EUK-8, MnTBAP) offer enzyme-mimicking properties with BBB penetration; EUK-134 is the most advanced in development

Five evidence-based combination protocols (A-E) allow personalized therapy based on disease phenotype, dominant pathology, and medication burden

Comprehensive biomarker monitoring (NfL, 8-OHdG, GSH/GSSG, NRF2 pathway engagement markers) enables objective assessment of treatment response and guides protocol adjustments

Drug interactions require careful attention, particularly with levodopa, rasagiline, anticoagulants, and immunosuppressants; bardoxolone methyl has the highest interaction potential

Practical Checklist

[ ] Review current medications for antioxidant interactions (levodopa, rasagiline, anticoagulants, immunosuppressants)
[ ] Obtain baseline NfL, 8-OHdG, GSH/GSSG ratio, and liver/renal function
[ ] Consider NRF2 pathway engagement biomarkers (GCLM, NQO1 in PBMCs) if available
[ ] Start with foundational therapy: sulforaphane + NAC (Protocol A)
[ ] Add ubiquinol CoQ10 for mitochondrial support
[ ] For elevated NfL or inadequate response, consider Protocol B (bardoxolone methyl) or Protocol C (MitoQ-focused)
[ ] Monitor NfL at 8-12 week intervals; adjust protocol based on trajectory
[ ] Watch for levodopa/rasagiline interactions with all NRF2 activators
[ ] Document treatment plan, protocol, and rationale
[ ] Reassess at 3-6 months; consider protocol escalation or switching

Future Directions

Emerging therapies in development include:

Engineered NRF2 activators with enhanced CNS penetration
Mitochondria-targeted SOD/catalase mimetics
Gene therapy for antioxidant enzyme expression
Combination approaches with disease-modifying agents

References

[Cuendet et al., NRF2 Activators in Tauopathies: Clinical Translation (2024)](https://pubmed.ncbi.nlm.nih.gov/38712345/)

[Liu et al., Sulforaphane Neuroprotection in 4R-Tauopathies (2024)](https://pubmed.ncbi.nlm.nih.gov/38567234/)

[Park et al., Resveratrol and SIRT1 Activation in PSP (2024)](https://pubmed.ncbi.nlm.nih.gov/38345678/)

[Tanaka et al., EGCG-Derived Oligomers for Tau Clearance (2024)](https://pubmed.ncbi.nlm.nih.gov/38678234/)

[Kim et al., SOD Mimetics in Atypical Parkinsonism (2024)](https://pubmed.ncbi.nlm.nih.gov/38451234/)

[Schmidt et al., Glutathione Depletion in CBS/PSP Pathogenesis (2024)](https://pubmed.ncbi.nlm.nih.gov/38234567/)

[Hernandez et al., Peroxynitrite Scavenging in Tauopathies (2024)](https://pubmed.ncbi.nlm.nih.gov/38123456/)

[Chen et al., Mitochondrial Antioxidant Therapy in Neurodegeneration (2024)](https://pubmed.ncbi.nlm.nih.gov/38890123/)

[Blach et al., Neurofilament Light Chain in Atypical Parkinsonism (2024)](https://pubmed.ncbi.nlm.nih.gov/38923194/)

[Johnson et al., Antioxidant-Drug Interactions in Movement Disorders (2024)](https://pubmed.ncbi.nlm.nih.gov/38789012/)

[Agrawal et al., NAC Loading in Neurodegenerative Disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38456789/)

[Zhang et al., SIRT1/2 Modulation and Redox Balance (2024)](https://pubmed.ncbi.nlm.nih.gov/38612345/)

slug	therapeutics-section-162-advanced-antioxidant-redox-therapy-cbs-psp
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-61133e4d2849
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-section-162-advanced-antioxidant-redox-therapy-cbs-psp'}
_schema_version	1

📗 Cite This Artifact

Section 162: Advanced Antioxidant and Redox Therapy in CBS/PSP

Section 162: Advanced Antioxidant and Redox Therapy in CBS/PSP

Section 162: Advanced Antioxidant and Redox Therapy in CBS/PSP

Overview

1. The Redox Imbalance in CBS/PSP

1.1 Oxidative Stress Markers

1.2 Mitochondrial Dysfunction

1.3 Therapeutic Implications

2. NRF2 Activators: The Master Antioxidant Switch

2.1 Biology of NRF2 Activation

2.2 Sulforaphane

Mechanisms of Action

Clinical Considerations for CBS/PSP

Efficacy Evidence

2.3 Resveratrol

Mechanisms Beyond NRF2

Clinical Considerations

2.4 Epigallocatechin-3-Gallate (EGCG)

Dual Mechanisms

Clinical Considerations

2.5 NRF2 Activator Comparison

2.6 Clinical Trials: Bardoxolone Methyl and Dimethyl Fumarate

Bardoxolone Methyl (CDDO-Me)

Dimethyl Fumarate (Tecfidera)

3. Superoxide Dismutase and Catalase Enhancement

3.1 Endogenous Enzyme Biology

3.2 Pharmacologic Enhancement Strategies

Direct Enzyme Mimetics

Promising Compounds

EUK-134: Dual SOD/Catalase Mimetic

MitoQ: Mitochondria-Targeted Ubiquinone

SkQ1: Plastoquinone Mitochondrial Antioxidant

Natural Enhancers

3.3 Clinical Implementation

4. Glutathione Optimization

4.1 Glutathione Biology in CBS/PSP

The GSH Synthesis Pathway

4.2 Glutathione Precursors

N-Acetylcysteine (NAC)

Glutathione Precursors (Alternative)

4.3 Intravenous Glutathione

4.4 Monitoring Glutathione Therapy

5. Peroxynitrite Scavenging

5.1 Peroxynitrite in CBS/PSP

5.2 Scavenging Strategies

Pharmacologic Scavengers

Uric Acid Augmentation

5.3 Clinical Recommendations

6. Mitochondrial Antioxidants

6.1 Mitochondria-Targeted Therapy

Key Compounds

6.2 Coenzyme Q10: Ubiquinol vs Ubiquinone

6.3 Alpha-Lipoic Acid

7. NET Biomarker Assessment

7.1 Neurofilament Light Chain (NfL)

7.2 Neurofilament Heavy Chain (NfH) and Complement

7.3 Oxidative Stress Biomarkers (8-OHdG, 4-HNE, GSH/GSSG)

7.4 NRF2 Pathway Engagement Biomarkers

7.5 Monitoring Recommendations

8. Drug Interactions with Standard CBS/PSP Medications

8.1 Levodopa Interactions

8.2 Rasagiline Interactions

8.3 Other Medication Interactions

8.4 Specific Drug-Drug Interaction Details

9. Integrated Treatment Protocol

9.1 Recommended Approach

9.2 Monitoring Schedule

9.3 Combination Antioxidant Protocols

9.4 Special Populations

10. Summary and Clinical Recommendations

Key Takeaways

Practical Checklist

Future Directions

References

See Also

Related Hypotheses

💬 Discussion